The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Khat’kova S.E.

Treatment Rehabilitation Center

Pogorel’tseva O.A.

Treatment Rehabilitation Center

Kilina A.P.

National Medical Research Center for Rehabilitation

Knyazev A.V.

Merz Pharma LLC

Evaluation of the efficacy and safety of botulinum toxin type A injections for the prevention of aspiration complications in patients with neurogenic dysphagia and posterior sialorrhea of various etiologies

Authors:

Khat’kova S.E., Pogorel’tseva O.A., Kilina A.P., Knyazev A.V.

More about the authors

Read: 664 times


To cite this article:

Khat’kova SE, Pogorel’tseva OA, Kilina AP, Knyazev AV. Evaluation of the efficacy and safety of botulinum toxin type A injections for the prevention of aspiration complications in patients with neurogenic dysphagia and posterior sialorrhea of various etiologies. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(12):126‑133. (In Russ.)
https://doi.org/10.17116/jnevro2025125121126

Recommended articles:
Frequency of nutritional defi­ciency in patients with Alzheimer’s disease and Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(12):113-119
Surgery for recu­rrent benign tracheoesophageal fistula. Piro­gov Russian Journal of Surgery. 2026;(2):36-42

References:

  1. Ivolgin AF, Avseitseva TYu, Kurenkov AL, et al. Treatment of sialorrhea in adults and children using botulinum toxin type A. L.O. Badalyan Neurological Journal. 2023;4(4):200-207. (In Russ.). https://doi.org/10.46563/2686-8997-2023-4-4-200-207
  2. Bril EV, Fedotova NA, Zimnyakova OS, et al. Diagnosis and treatment approaches for sialorrhea in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(10):29-34. (In Russ.). https://doi.org/10.17116/jnevro202412410129
  3. Borzdyko AA, Ershov VI, Mezhebovsky VR. Predicting the development of aspiration pneumonia in patients with ischemic stroke and neurogenic dysphagia. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(6):57-62. (In Russ.). https://doi.org/10.17116/jnevro202312306157
  4. Wang L, Li A, Zhang C, et al. Sublingual administration of atropine eye drops for treating sialorrhea after stroke: A randomized controlled trial. J Stroke Cerebrovasc Dis. 2024;33(12):108050. https://doi.org/10.1016/j.jstrokecerebrovasdis.2024.108050
  5. Gerasimova MA. Contribution of Pneumonia in Maintaining a High Mortality from Strokes and Their Consequnces (Literature Review). Human Ecology. 2020;2:23-29. (In Russ.).
  6. Mata S, Blánquez B, Serrano F. The Oropharyngeal Dysphagia Screening Test for Patients and Professionals: Validation in Cognitive Impairment and in Severe Mental Illness. Dysphagia. 2025;40(1):98-109.  https://doi.org/10.1007/s00455-024-10707-0
  7. Banda KJ, Chu H, Kang XL, et al. Prevalence of dysphagia and risk of pneumonia and mortality in acute stroke patients: a metaanalysis. BMC Geriatr. 2022;22(1):420.  https://doi.org/10.1186/s12877-022-02960-5
  8. Khat’kova SE, Pogorel’tseva OA. Algorithms for the diagnosis and treatment of cognitive impairment and dysphagia in stroke patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(4-2):100-107. (In Russ.). https://doi.org/10.17116/jnevro2024124042100
  9. Silva MA, da Silveira M, Pedrosa B, et al. A systematic review of the perspectives of botulinum toxin use on the quality of life of neurological patients with drooling. Clin Oral Investig. 2024;28(6):322.  https://doi.org/10.1007/s00784-024-05718-y
  10. Shao M, Chen K, Wu X et al. Botulinum toxin in the treatment of sialorrhea in severe neurological patients with tracheotomy. Brain Behav. 2023;13(8):e3164. https://doi.org/10.1002/brb3.3164
  11. Xu H, Ge H, Cai Z. Botulinum toxin type a blocks aquaporin 5 trafficking by decreasing synaptosomal-associated protein 23 in submandibular acinar cells. Exp Cell Res. 2024;436(2):113954. https://doi.org/10.1016/j.yexcr.2024.113954
  12. Morgante F, Bavikatte G, Anwar F, et al. The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin). Ther Adv Neurol Disord. 2019;12:1756286419888601. https://doi.org/10.1177/1756286419888601
  13. Jost WH, Kaňovský P, Hast MA, et al. Pooled Safety Analysis of IncobotulinumtoxinA in the Treatment of Neurological Disorders in Adults. Toxins (Basel). 2023;15(6):353.  https://doi.org/10.3390/toxins15060353
  14. Slouha E, Ibrahim F, Esposito S, et al. Botulinum Toxin for the Management of Parkinson’s Disease: A Systematic Review. Cureus. 2024;16(1):e53309. https://doi.org/10.7759/cureus.53309
  15. McHenry KL. Airway Clearance Strategies and Secretion Management in Amyotrophic Lateral Sclerosis. Respir Care. 2024;69(2):227-237.  https://doi.org/10.4187/respcare.11215
  16. Mazlan M, Rajasegaran S, Engkasan JP, et al. A double-blind randomized controlled trial investigating the most efficacious dose of botulinum toxin-A for sialorrhea treatment in Asian adults with neurological diseases. Toxins. 2015;7(9):3758-3770. https://doi.org/10.3390/toxins7093758
  17. Chinnapongse R, Gullo K, Nemeth P, et al. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson’s disease: a prospective double-blind trial. Mov Disord. 2012;27(2):219-226.  https://doi.org/10.1002/mds.23929
  18. Guidubaldi A, Fasano A, Ialongo T, et al. Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson’s disease. Mov Disord. 2011;26(2):313-319.  https://doi.org/10.1002/mds.23473
  19. Ischemic stroke and transient ischemic attack. Clinical guidelines. Ministry of Health of the Russian Federation. 2024. (In Russ.).
  20. Jost WH, Friedman A, Michel O, et al. SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea. Neurology. 2019;92(17):e1982-e1991. https://doi.org/10.1212/WNL.0000000000007368
  21. Berweck S, Bonikowski M, Kim H, et al. Placebo-Controlled Clinical Trial of IncobotulinumtoxinA for Sialorrhea in Children: SIPEXI. Neurology. 2021;97(14):e1425-e1436. https://doi.org/10.1212/WNL.0000000000012573
  22. Rehabilitation in the intensive care unit (RehabICU). Clinical practice recommendations of the national Union of Physical and Rehabilitation Medicine Specialists of Russia and of the national Federation of Anesthesiologists and Reanimatologists. 2023. (In Russ.).
  23. Clark T, Arikan E, Bradley L. The effectiveness and safety of botulinum toxin treatment for sialorrhea due to severe brain injury. Brain Injury. 2025;39(6):476-481.  https://doi.org/10.1080/02699052.2024.2444536
  24. Gusev VV, Balueva TV, Zayceva OV, Smirnov DA. Use of botulinum toxin in patients with dysphagia and sialorrhea in acute ischemic stroke. Neurology, Neuropsychiatry, Psychosomatics. 2025;17(2):30-35. (In Russ.). https://doi.org/10.14412/2074-2711-2025-2-30-35

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.